Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

NCT04181060 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT04181060
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04181060 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 3
Overall status
Recruiting
Start date
December 28, 2020
Completion date
June 30, 2029
Enrollment
300 (estimated)
Sites
603

Conditions

As the registry lists them; a condition with its own page is linked.

advanced lung non-squamous non-small cell carcinoma, metastatic lung non-squamous non-small cell carcinoma, recurrent lung non-squamous non-small cell carcinoma, stage iiib lung cancer ajcc v8, stage iv lung cancer ajcc v8